ClinicalTrials.gg
RecruitingNCT06541067POSALLOUpdated Nov 19, 2026

Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)

A Phase 2 interventional study of Posaconazole in Hematologic Malignancy, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Planned enrollment
84th of 107
30 · median 106
Started
2024
with 7 others
Phase 2
24 of 142
8 open now
Primary completion
2026-09
later than 15 of 57 live
Registered
125th of 142
by date
Lead sponsor
5 of 142
Nantes University Hospital

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 84th largest by planned enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2024, is one of 24 in phase 2, reaches primary completion later than 15 of the 57 other live ones, and was the 125th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

Patients receiving an allogeneic hematopoietic stem cell transplant (allo-CSH) are at high risk of infection, particularly of fungal origin. Until the 2018 recommendations of the 6th European Conference on Infections in Leukemia (ECIL6), primary prophylaxis of invasive fungal infections (IFI), in allograft patients, was based on the administration of fluconazole until D100. Due to changes in transplantation practices (alternative donor transplantation, sequential transplantation, etc.) and changes in microbiological ecology (increased incidence of IFIs caused by filamentous germs such as aspergillosis and mycormycosis), fluconazole prophylaxis is now sometimes suboptimal. It is therefore recommended that patients at high risk of developing IFIs should be given azole molecules with activity against filamentous agents as primary prophylaxis during the first 3 months after transplantation.

Posaconazole is often under-dosed (below the minimum effective concentration). It therefore seems essential to carry out a prospective study with close [C]min dosing in the specific situation of allograft patients, a population that appears to be at risk of underdosing in the light of initial retrospective analysis results.

Read the detailed description

There are several treatments based on azole molecules: voriconazole, posaconazole, isavuconazole... To date, none of these treatments has been approved for primary post-allograft prophylaxis. Posaconazole is indicated in cases of graft-versus-host disease (GVHD) (requiring systemic corticosteroid therapy after allo-CSH), and as primary prophylaxis during aplasia in patients with acute myeloblastic leukemia/myelodysplasia (AML/MDS). Other azole molecules are not approved for primary prophylaxis, and may give rise to drug interactions with certain treatments prescribed for allograft patients (e.g. ciclosporin, letermovir).

Although recommendations for the administration of posaconazole as primary prophylaxis post allo-CSH have been in place for 4 years, few studies are available to date. The adult hematology department of Nantes University Hospital conducted a retrospective study of 70 allograft patients at high risk of IFI between 04/2020 and 12/2021. Posaconazole treatment was administered from D0 (or the day after the 2nd dose of post-transplant cyclophosphamide) to D100. Treatment was generally well tolerated, with discontinuation due to possible treatment toxicity in 12.6% of cases, mainly of hepatic origin (n=7). Posaconazole was resumed in 2 cases without recurrence of toxicity. In 84.2% of patients, no IFI was observed. One of the limitations of this study was the low number of determinations of residual posaconazole concentration ([C]min). In fact, [C]min was carried out in only 59 patients/70, with a median delay of 9 days. In 43% of cases, the [C]min was insufficient (\< 0.5 mg/L), which is significantly lower than the [C]min obtained in patients with AML/MDS undergoing induction ([C]min\< 0.5 mg/L: 5% of patients). It therefore seems essential to carry out a prospective study with close [C]min measurement in the specific situation of allograft patients, a population that appears to be at risk of underdosing in the light of the initial retrospective results of analyses.

03

Conditions studied

  • Hematologic Malignancy

Keywords

  • Hematopoietic stem cell allograft (Allo-CSH)
  • Posaconazole
  • Pharmacology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years of age. There is no maximum age for inclusion
  • Allo-CSH transplant for hematologic or benign hemopathy of any type with one or more high risk IFI criteria:

    • alternative donor (haploidentical intra-family donor, mismatch file donor, placental blood)
    • sequential conditioning for disease not in remission at the time of transplantation
    • use of post-transplant cyclophosphamide (PTCY) for GVH prophylaxis
    • patient who has previously received a HSC allograft
  • Written prior to protocol initiation
  • \<=2
  • Female of childbearing age with negative pregnancy test and on highly effective during treatment and for 12 months after posaconazole discontinuation
  • Men of childbearing age with effective contraception during treatment and for 6 months after stopping posaconazole.
  • , C and serologies negative.
  • Social security affiliation

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of IFI, whether active or resolved at the time of allografting
  • Patient with known intolerance to posaconazole
  • Patients with concomitant treatments FORBIDDING association with posaconazole: ergot alkaloids, substrates (terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine), HMG-CoA reductase inhibitors (simvastatin, lovastatin and atorvastatin) or any other treatment listed in VIDAL
  • patients with congenital or acquired prolongation (QTc >470ms)
  • Cardiac: systolic \< 50% by transthoracic ultrasound or isotopic method (isotopic gamma-angiography)
  • Respiratory: DLCOc \<40% of theoretical on EFR
  • Renal: \< 50 ml/min (assessed using method)
  • Hepatic: transaminases greater than 5 times normal or greater than 2 times normal
  • Pregnant or breast-feeding women,
  • Women or men of childbearing age without effective
  • Serious, uncontrolled concomitant infections
  • Yellow fever vaccination within the last year
  • Patient protected by law (guardianship, curatorship, safeguard of justice)
  • Psychological, family, sociological or geographical conditions that may hinder compliance with the study protocol and follow-up schedule
  • Patient who does not speak or understand French
  • Participation in any other therapeutic study with an exclusion period still in effect at the time of inclusion or planned participation in another therapeutic study while taking posaconazole
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Posaconazole

    Drug: Posaconazole

Interventions

  • Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols). On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose

06

What researchers measure

Primary outcomes

  1. Effective residual concentration of posaconazole

    The main objective is to study, in the early phase after allo-CSH, the percentage of patients who have an effective residual concentration of posaconazole. The primary endpoint is plasma residual posaconazole concentration (\[C\]min), measured on day 8 of posaconazole initiation. A \[C\]min \> 0.7mg/l is considered effective.

    Time frame: On the 8th day of treatment (i.e. after 7 days of treatment)

Secondary outcomes

  1. Monitoring of residual plasma concentrations [C]min

    Weekly residual plasma concentrations of posaconazole

    Time frame: From posaconazole baseline up to Day100

  2. Description of circumstances leading to posaconazole underdosing

    A clinical record will be taken twice a week during hospitalization and then once a week to describe clinical symptoms leading to malabsorption: nausea, vomiting, diarrhea, mucositis, colitis. Symptom intensity will be assessed according to the NCI CTCAE v5 classification

    Time frame: From posaconazole baseline up to Day100

  3. Description of circumstances leading to posaconazole underdosing

    Adherence to treatment will be monitored daily during hospitalization by paramedical staff. Once home, adherence will be assessed once a week by the doctor in charge of the patient

    Time frame: From posaconazole baseline up to Day100

  4. Description of circumstances leading to posaconazole underdosing

    All co-medications should be recorded throughout the course of posaconazole treatment, based on data from the patient's medical record

    Time frame: From posaconazole baseline up to Day100

  5. Description of the reasons for administering posaconazole intravenously (IV)

    The physician in charge of the patient should specify the reason(s) for IV administration of the treatment

    Time frame: From posaconazole baseline up to Day100

  6. Description of situations leading to initial non-administration or early discontinuation of posaconazole

    The physician in charge of the patient should specify the situation(s) that led to non-administration or early discontinuation of treatment.

    Time frame: From posaconazole baseline up to Day100

  7. Description of situations leading to initial non-administration or early discontinuation of posaconazole

    Description of posaconazole-related toxicities according to NCI CTCAE v5 classification

    Time frame: From posaconazole baseline up to Day 100

  8. Description of invasive fungal infections occurring

    Description of IFI cases according to EORTC classification

    Time frame: From posaconazole baseline up to 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study)

  9. Description of patient outcome: incidence of engraftment

    Engraftment assessed on hematological reconstitution (number of days of aplasia with PNN \<0.5 G/L and platelets \< 20, number of platelet and packed cell transfusions)

    Time frame: Month 1 post-transplant

  10. Description of patient outcome: overall survival (OS)

    Survival between day 0 of transplantation and date of death or last follow-up

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study) or death

  11. Description of patient outcome: disease-free survival (DFS)

    Survival between day 0 of transplant and date of relapse, death or last follow-up

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study) or documented relapse or death whicvever came first

  12. Description of patient outcome: non-relapse mortality (NRM)

    Any death unrelated to relapse or disease progression

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study) or death, whichever came first

  13. Description of patient outcome: incidence of relapse (IR)

    Any documented disease recurrence

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study) or any documented disease recurrence, whichever came first

  14. Description of patient outcome: cumulative incidence of acute GVHD

    Acute GVH grade 2-4 according to Mount Sinai criteria

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study)

  15. Description of patient outcome: cumulative incidence of chronic GVHD

    Extensive chronic GVH according to NCI criteria

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study)

  16. Description of patient outcome: GVHD-free relapse-free survival (GRFS)

    Median relapse-free survival without grade 3-4 acute GVHD or chronic GVHD requiring systemic treatment

    Time frame: Up to Day100 and 1 year post-transplant and/or through study completion (end of follow-up at the last visit of the last patient included in the study) or death

  17. Grade 3 and 4 post-transplant adverse events

    Post-transplant grade 3 and 4 adverse events (dates of occurrence) (NCI CTCAE version 5 criteria)

    Time frame: Up to Day100 and 1 year post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Sep 2026, 22 months.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's 22 months is below that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2027 → Sep 2026 and completion Nov 2028 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Aug 7, 2024
StartActual
Nov 8, 2024
Primary completionActual
Sep 9, 2026was Jan 2027
CompletionEst.
Jun 2027was Nov 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • CHU Nantes · Nantes, France
Show 1 removed
  • CHU Nantes · Nantes, France
Nov 19, 2026
Primary completion
Jan 15, 2027→Sep 9, 2026 (actual)
Nov 19, 2026
Study completion
Nov 8, 2028→Jun 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added, 1 site removed
    Show site
    • CHU Nantes · Nantes, France
    Show 1 removed
    • CHU Nantes · Nantes, France
    Primary completion Jan 15, 2027→Sep 9, 2026 (now actual)
    Study completion Nov 8, 2028→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06541067
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Nov 8, 2024
Primary completion
Sep 9, 2026
Completion
Jun 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Amandine LE BOURGEOIS, MD
Contact
amandine.lebourgeois@chu-nantes.fr
02 40 08 32 71 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Posaconazole

Start the discussion